Cargando…

Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a strong risk factor for liver fibrosis in non-alcoholic fatty liver disease (NAFLD). It remains uncertain why T2DM increases the risk of liver fibrosis. It has been suggested that growth differentiation factor-15 (GDF-15) concentrations increase the ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilson, Josh, Scorletti, Eleonora, Bindels, Laure B., Afolabi, Paul R., Targher, Giovanni, Calder, Philip C., Sethi, Jaswinder K., Byrne, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523689/
https://www.ncbi.nlm.nih.gov/pubmed/34663793
http://dx.doi.org/10.1038/s41387-021-00170-3
_version_ 1784585343466471424
author Bilson, Josh
Scorletti, Eleonora
Bindels, Laure B.
Afolabi, Paul R.
Targher, Giovanni
Calder, Philip C.
Sethi, Jaswinder K.
Byrne, Christopher D.
author_facet Bilson, Josh
Scorletti, Eleonora
Bindels, Laure B.
Afolabi, Paul R.
Targher, Giovanni
Calder, Philip C.
Sethi, Jaswinder K.
Byrne, Christopher D.
author_sort Bilson, Josh
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (T2DM) is a strong risk factor for liver fibrosis in non-alcoholic fatty liver disease (NAFLD). It remains uncertain why T2DM increases the risk of liver fibrosis. It has been suggested that growth differentiation factor-15 (GDF-15) concentrations increase the risk of liver fibrosis. We aimed to investigate (a) whether GDF-15 concentrations were associated with liver fibrosis and involved in the relationship between T2DM and liver fibrosis and (b) what factors linked with T2DM are associated with increased GDF-15 concentrations. METHODS: Ninety-nine patients with NAFLD (61% men, 42.4% T2DM) were studied. Serum GDF-15 concentrations were measured by electro-chemiluminescence immunoassay. Vibration-controlled transient elastography (VCTE)-validated thresholds were used to assess liver fibrosis. Regression modelling, receiver operator characteristic curve analysis and Sobel test statistics were used to test associations, risk predictors and the involvement of GDF-15 in the relationship between T2DM and liver fibrosis, respectively. RESULTS: Patients with NAFLD and T2DM (n = 42) had higher serum GDF-15 concentrations [mean (SD): 1271.0 (902.1) vs. 640.3 (332.5) pg/ml, p < 0.0001], and a higher proportion had VCTE assessed ≥F2 fibrosis (48.8 vs. 23.2%, p = 0.01) than those without T2DM. GDF-15 was independently associated with liver fibrosis (p = 0.001), and GDF-15 was the most important single factor predicting ≥F2 or ≥F3 fibrosis (≥F2 fibrosis AUROC 0.75, (95% CI 0.63–0.86), p < 0.001, with sensitivity, specificity, positive predictive (PPV) and negative predictive (NPV) values of 56.3%, 86.9%, 69.2% and 79.1%, respectively). GDF-15 was involved in the association between T2DM and ≥F2 fibrosis (Sobel test statistic 2.90, p = 0.004). Other factors associated with T2DM explained 60% of the variance in GDF-15 concentrations (p < 0.0001). HbA1c concentrations alone explained 30% of the variance (p < 0.0001). CONCLUSIONS: GDF-15 concentrations are a predictor of liver fibrosis and potentially involved in the association between T2DM and liver fibrosis in NAFLD. HbA1c concentrations explain a large proportion of the variance in GDF-15 concentrations.
format Online
Article
Text
id pubmed-8523689
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85236892021-11-04 Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD Bilson, Josh Scorletti, Eleonora Bindels, Laure B. Afolabi, Paul R. Targher, Giovanni Calder, Philip C. Sethi, Jaswinder K. Byrne, Christopher D. Nutr Diabetes Article BACKGROUND: Type 2 diabetes mellitus (T2DM) is a strong risk factor for liver fibrosis in non-alcoholic fatty liver disease (NAFLD). It remains uncertain why T2DM increases the risk of liver fibrosis. It has been suggested that growth differentiation factor-15 (GDF-15) concentrations increase the risk of liver fibrosis. We aimed to investigate (a) whether GDF-15 concentrations were associated with liver fibrosis and involved in the relationship between T2DM and liver fibrosis and (b) what factors linked with T2DM are associated with increased GDF-15 concentrations. METHODS: Ninety-nine patients with NAFLD (61% men, 42.4% T2DM) were studied. Serum GDF-15 concentrations were measured by electro-chemiluminescence immunoassay. Vibration-controlled transient elastography (VCTE)-validated thresholds were used to assess liver fibrosis. Regression modelling, receiver operator characteristic curve analysis and Sobel test statistics were used to test associations, risk predictors and the involvement of GDF-15 in the relationship between T2DM and liver fibrosis, respectively. RESULTS: Patients with NAFLD and T2DM (n = 42) had higher serum GDF-15 concentrations [mean (SD): 1271.0 (902.1) vs. 640.3 (332.5) pg/ml, p < 0.0001], and a higher proportion had VCTE assessed ≥F2 fibrosis (48.8 vs. 23.2%, p = 0.01) than those without T2DM. GDF-15 was independently associated with liver fibrosis (p = 0.001), and GDF-15 was the most important single factor predicting ≥F2 or ≥F3 fibrosis (≥F2 fibrosis AUROC 0.75, (95% CI 0.63–0.86), p < 0.001, with sensitivity, specificity, positive predictive (PPV) and negative predictive (NPV) values of 56.3%, 86.9%, 69.2% and 79.1%, respectively). GDF-15 was involved in the association between T2DM and ≥F2 fibrosis (Sobel test statistic 2.90, p = 0.004). Other factors associated with T2DM explained 60% of the variance in GDF-15 concentrations (p < 0.0001). HbA1c concentrations alone explained 30% of the variance (p < 0.0001). CONCLUSIONS: GDF-15 concentrations are a predictor of liver fibrosis and potentially involved in the association between T2DM and liver fibrosis in NAFLD. HbA1c concentrations explain a large proportion of the variance in GDF-15 concentrations. Nature Publishing Group UK 2021-10-18 /pmc/articles/PMC8523689/ /pubmed/34663793 http://dx.doi.org/10.1038/s41387-021-00170-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bilson, Josh
Scorletti, Eleonora
Bindels, Laure B.
Afolabi, Paul R.
Targher, Giovanni
Calder, Philip C.
Sethi, Jaswinder K.
Byrne, Christopher D.
Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title_full Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title_fullStr Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title_full_unstemmed Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title_short Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
title_sort growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in nafld
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523689/
https://www.ncbi.nlm.nih.gov/pubmed/34663793
http://dx.doi.org/10.1038/s41387-021-00170-3
work_keys_str_mv AT bilsonjosh growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT scorlettieleonora growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT bindelslaureb growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT afolabipaulr growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT targhergiovanni growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT calderphilipc growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT sethijaswinderk growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld
AT byrnechristopherd growthdifferentiationfactor15andtheassociationbetweentype2diabetesandliverfibrosisinnafld